The Impact of HLA-C Matching on Donor Identification Rates in a European-Caucasian Population by Hans-Peter Eberhard & Carlheinz R. MÃ¼ller
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 15 October 2014
doi: 10.3389/fimmu.2014.00501
The impact of HLA-C matching on donor identification rates
in a European-Caucasian population
Hans-Peter Eberhard and Carlheinz R. Müller*
Zentrales Knochenmarkspender-Register Deutschland (ZKRD), Ulm, Germany
Edited by:
AntoineToubert, Université Paris
Diderot, France
Reviewed by:
Ralf Dressel, University Medical
Center Göttingen, Germany
Nicolas Dulphy, Université Paris
Diderot, France
Alain Haziot, Institut National pour la
Santé et la Recherche Médicale
(INSERM), France
*Correspondence:
Carlheinz R. Müller , Zentrales
Knochenmarkspender-Register
Deutschland (ZKRD), POB 4244, Ulm
89032, Germany
e-mail: carlheinz.mueller@zkrd.de
The degree of HLA concordance with the patient has long been known to be the major
donor-related prediction factor for the success of hematopoietic stem cell transplantations
and, with the progress of HLA typing technology, selection criteria became more stringent
with regard to the recommended loci and resolution. A late refinement was HLA-C match-
ing, which gained broader acceptance only after the turn of the millennium.The enormous
HLA polymorphism has always necessitated registries with a large number of donors in
order to be able to provide well-matched donors to a substantial fraction of patients. Using
a biostatistical approach, we investigated the impact of adding HLA-C at low or high reso-
lution as a supplementary matching criterion on some key parameters in donor provision
for a European-Caucasian population. Starting point is donor selection based on allele level
matching for HLA-A, -B, -DRB1, and, optionally, HLA-DQB1.Without typing for HLA-C, 68%
of the donors selected based on matching for HLA-A, -B, -DRB1, and -DQB1 at high reso-
lution will also match for HLA-C, 29% will have a single and only 3% will have two HLA-C
alleles different from the patient. In order to provide the same fraction of patients with a
fully matched donor, a registry would have to be about twice the size if HLA-C is considered
in addition to the four other loci, with the exact factor increasing with the registry’s size. If
the provision of donors with up to a single allele mismatch is considered, this factor doubles
due to the strong linkage between HLA-B and -C.These figures only change slightly when
HLA-DQB1 is completely ignored or HLA-C matching is only considered at low resolution.
Our results contribute to quantifying the medical and economic impact of the progress in
donor selection algorithms.
Keywords: HLA-C, haplotype frequency estimation, donor registry, hematopoietic stem cell transplantation,
donor-patient matching, donor identification rate
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) is a
well-established therapy with curative potential for malignant dis-
eases of the blood and numerous otherwise fatal non-malignant
disorders (1, 2). The degree of HLA matching with the patient
has long been known to be the major donor-related factor pre-
dicting the success of a HSCT (3–5). With the progress of HLA
typing technology during the last decades, the number of loci and
the typing resolution used in donor selection have continuously
increased. Typing and matching for HLA-A, -B, and -DR(B1) was
a long-term practice in the 1980s and 1990s when serological and
cellular testing were gradually replaced by molecular technology,
first for class II and later for class I, boosting the reproducibility
and resolution of typing results (6, 7). While the attention paid to
HLA-DQB1 has varied, in spite of earlier indications of its rele-
vance (8) HLA-C was largely neglected until after the turn of the
millennium (9, 10). In earlier days, the low quality of serological
HLA-C testing, the strong HLA-B, -C linkage, and the habit of
experts to misuse this linkage in the interpretation of inconclu-
sive laboratory data for HLA-C hampered establishing HLA-C as
transplantation antigen. After the analyses of Flomenberg, Lee,
and Woolfrey (11–13) during the last decade, HLA-C is now
routinely considered in donor selection (14–16), but discussions
are still ongoing as to if doing so at low resolution would be
sufficient (13, 17).
Haplotype frequency estimation (HFE) from phenotypic pop-
ulation data is well-established (18–20) and the challenges posed
by the size of registry-derived datasets and their inherent ambi-
guities and heterogeneities have intensively been studied (20, 21).
In return, these haplotype frequencies (HF) can be used to study
certain population properties, in particular, the dependence of the
supply of donors on the size of a registry of volunteers from the
population (19, 22–25).
In this study, we will investigate the impact of HLA-C matching
on the donor procurement rates in a European-Caucasian popu-
lation as well as the growth required for a registry to keep up its
procurement rate when confronted with more stringent HLA-C
matching criteria. Due to the heterogeneity of common practice
with regard to HLA-DQB1 (15, 26), we will present results for
matching procedures including and disregarding HLA-DQB1.
MATERIALS AND METHODS
We have estimated five-locus HLA-A, -B, -C, -DRB1, -DQB1 HF at
high resolution (i.e., using the first two fields of the allele names)
from a snapshot of the German donor database at the ZKRD
(Zentrales Knochenmarkspender-Register Deutschland, i.e., the
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FIGURE 1 |The curves show the percentage of patients capable
of finding a matched donor depending on the size of the
registry (horizontal axis in logarithmic scale) according to
various typing resolutions (HLA-C matching considered at high
or low resolution or not at all; continuous, dashed,
dashed-and-dotted) and the maximum number of mismatches
allowed (0, 1, or 2; green, blue, or red). All matching includes
HLA-A, -B, -DRB1, and -DQB1.
German National Stem Cell Donor Registry) from May 2014,
including 2,001,575 individuals with HLA designations at mol-
ecular level for HLA-A, -B, -C, -DRB1, and -DQB1. All HLA
assignments used are based on the IMGT/HLA Database Release
3.16.0, 2014-04-14 (27) and the World Marrow Donor Association
guidelines for the use of the HLA nomenclature (28, 29).
The HFE was performed using our well-established (19, 21)
and validated (30) HFE program, which was further tuned to han-
dle the increased ambiguity and size of this sample. This allowed
for the inclusion of all donors with molecular HLA typing data at
any resolution, leading to a sample size of over 2 million individu-
als. Allelic ambiguities were dealt with as described in (21). From
this dataset, the frequencies of 89,474 five-locus haplotype at high
resolution have been estimated. Since variations outside the anti-
gen recognition site (ARS, i.e., exon 2 and 3 for HLA class I and
exon 2 for HLA class II) are typically not taken into account for
donor selection (31–33), we have collapsed the frequencies of ARS
identical haplotypes yielding a final set of 83,446 ARS-level HF.
The probability of a random patient finding at least one suit-
ably matched donor within a given population of donors can be
calculated as
C (n) =
P∑
i=1
pi ×
(
1− (1− di)n
)
where P is the number of defined phenotypes, pi is the frequency
of the phenotype in the patient population, di is the cumulative
frequency of the suitably matched donors for this phenotype in the
donor population, and n is the number of donors in the registry
(24). In this calculation, the frequencies pi and di are easily derived
from the previously obtained HF and the result C(n) indicates the
extent to which the patient population is “covered” by a registry
of n donors. We will use the term “coverage” to refer to C(n),
depending on the registry size n and on the resolution of the hap-
lotypes of the underlying HF vector. The estimation of HF as well
as the calculation of phenotype frequencies from HF assumes that
the examined population is reasonably close to Hardy–Weinberg
equilibrium (HWE) and we know from previous studies (19, 21)
that the German donor population does not substantially deviate
from the HWE assumption.
In order to analyze various matching scenarios, from the full set
of 83,446 HF, we derived several marginal HF vectors by mapping
HLA-C alleles to low resolution (i.e., using only the first field of the
allele name) or dropping HLA-C and/or HLA-DQB1 completely
from the calculations performed. Moreover, we allowed one or
two mismatches in the matching criteria used to select the donors
contributing to the frequencies reflected in di above.
All calculations were performed on an IBM x3550 server with
192 GB RAM and 24 CPU kernels running at 3.47 GHz under
Ubuntu Linux 14.04. All time-critical parts of the HFE and the
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coverage calculations were written in C, whereas simpler tasks, like
data pre- and post-processing, were implemented in Perl. Statis-
tical analysis was performed with supportive Perl programs, stan-
dard spreadsheet software and the open source statistical package
“R” (34).
RESULTS
From the set of five-locus high-resolution HF, we have derived
five related sets of marginal frequencies. The six frequency vec-
tors are based on HLA-A, -B, -DRB1 at high resolution with C
missing or added at low or high resolution and, independently,
HLA-DQB1 added or omitted. For all six variants, we report the
coverage based on full matches (green curves in Figures 1 and
2; lines numbered 1–3 in Table 1) and single mismatches (blue
curves; lines numbered 4–6 in Table 1); however, we show the two
mismatch coverage only for the two variants including HLA-C at
high resolution (see also left part of Table 1).
The sets of lines with identical color in Figures 1 and 2 illus-
trate the influence of adding HLA-C at low and high resolution as
a matching criterion to high-resolution matching for HLA-A, -B,
-DRB1, -DQB1, and HLA-A, -B, -DRB1. These graphs allow for a
number of very interesting observations:
• The small difference between the dashed and the continu-
ous lines of the same color demonstrate that the HLA-C
polymorphism is already largely revealed at low resolution
among individuals allele-matched for the other three or four
loci.
• The large distance between the dashed-and-dotted green lines
and the other two green lines shows substantial further discrimi-
nation added by HLA-C at any resolution to three- or four-locus
allele matching.
• Likewise, the small difference between the corresponding green
lines in the two figures reflects the strong linkage between HLA-
DRB1 and -DQB1, also explaining the long ongoing debate
about the relevance of HLA-DQB1 as a criterion in HSCT.
• In contrast, the substantial difference between the correspond-
ing blue curves (one mismatch) in the two figures is quite
a surprise. The reason for this is primarily, again, the strong
HLA-DRB1-DQB1 linkage that shifts a substantial part of the
donors mismatched for HLA-DRB1 from the blue curves of
Figure 2 (one mismatch without considering HLA-DQB1) into
the higher red curve of Figure 1 (two mismatches) and, as a
consequence, brings down the blue curves.
• The red curves show that a registry of 1 million donors would
provide over 98% of the patients with an 8/10 donor and over
99% with a 6/8 donor (i.e., two high-resolution mismatches,
considering or ignoring HLA-DQB1). The distance from the
dashed-and-dotted blue line reflects donors fully matched for
HLA-C, but with two mismatches at other loci.
FIGURE 2 |The curves show the percentage of patients capable of
finding a matched donor depending on the size of the registry
(horizontal axis in logarithmic scale) according to various typing
resolutions (HLA-C matching considered at high or low resolution
or not at all; continuous, dashed, dashed-and-dotted) and the
maximum number of mismatches allowed (0, 1, or 2; green, blue,
or red). Here, all matching includes HLA-A, -B, and -DRB1, but not
HLA-DQB1.
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Table 1 |This table shows the attributes of the seven matching variants underlying the curves in Figures 1 and 2 and some of their key
coordinates, i.e., the number of donors required to reach a coverage of 25, 50, 75, and 90% (numbers below 1,000 and over 100,000,000 have
been blanked due to practical irrelevance and are also not reflected in the figures).
Curve Matching criteria Maximum no. of
mismatches
Thousand donors required to
cover patient fraction of
HLA-A, -B, -DRB1 HLA-C Allowed 25% 50% 75% 90%
Figure 1
1 Plus DQB1 High res. 0 47 602 8,879
2 Plus DQB1 Low res. 0 42 533 7,675 98,546
3 Plus DQB1 No 0 27 277 3,251 35,763
4 Plus DQB1 High res. 1 3 25 202 1,492
5 Plus DQB1 Low res. 1 3 20 163 1,171
6 Plus DQB1 No 1 1 6 35 218
7 Plus DQB1 High res. 2 2 13 64
Figure 2
1 No DQB1 High res. 0 38 458 6,292 77,603
2 No DQB1 Low res. 0 34 404 5,414 64,001
3 No DQB1 No 0 22 208 2,225 21,797
4 No DQB1 High res. 1 1 9 69 485
5 No DQB1 Low res. 1 1 7 56 385
6 No DQB1 No 1 3 15 82
7 No DQB1 High res. 2 1 3 14
Now, we can investigate the quantitative details of these curves
and first consider the vertical distance between the green curves.
Adding HLA-C matching at a registry size of 10,000 donors only
reduces the coverage compared with fully matched donors by
3% points, but this gap increases to almost 10% points beyond
1 million donors.
Conversely, considering the horizontal distance between the
green curves, maintaining the same coverage with the higher
matching requirements demands increasing the registry size. For
fully matched donors, the increment required is a factor between
two and three, whereas for single-mismatched donors this factor
ranges from three to around seven. Since this cannot easily be mea-
sured in the two figures due to the logarithmic scale of the x-axis,
we have added the four columns on the right of Table 1, revealing
these ratios.
As a by-product of the coverage calculations, we observed that
68% of the donors selected using high-resolution matching for
HLA-A, -B, -DRB1, -DQB1 are also a full match for HLA-C,
29% will have a single mismatch and only 3% will have a double
mismatch and even without including HLA-DQB1 upfront, the
corresponding numbers are virtually identical (67, 30, and 3%).
DISCUSSION
The important role of HLA-C matching for a successful HSCT is
well accepted today (5, 12, 13); however, the impact of a HLA-C
difference for the recipient may depend on stem cell source and
the type of mismatch present. The fact that over two-thirds of the
donors selected on the basis of HLA-A, -B, -DRB1 high-resolution
matching while omitting HLA-C are indeed HLA-C identical by
chance has contributed to the success of HSCTs preceding HLA-C
matching.
However, there is an important complementary aspect to this.
Figure 1 shows that, at a realistic registry size of 1 million donors,
64% of the patients have an HLA-A, -B, -DRB1, -DQB1 iden-
tical donor and 55% of the patients even have a donor that is
also identical for HLA-C. Without typing for HLA-C only 44%
of the patients would get a five-locus identical donor by chance.
Therefore, more than half, i.e. (55–44%)/(64–44%), of the remain-
ing mismatch situations could be avoided without increasing the
registry size merely by including HLA-C as a primary selection
criterion.
Maintaining the same rate of fully matched donors including
HLA-C requires increasing the size of a donor registry by a factor
of two to three. This may be achieved in European countries in
the near future if the forthcoming revolution in HLA typing by
next generation sequencing will hold its pricing promises. How-
ever, if single mismatch transplants are considered, the step from
≥7/8 to ≥9/10 matching is substantially higher since many HLA-
B mismatches are typically accompanied by the corresponding
HLA-C mismatch so that the size of the donor file would have
to grow by a factor of three to seven to maintain the previous
procurement rate.
Over 98% of the patients would have a≥8/10 identical donor in
a registry of 1 million donors so that accepting a second mismatch
would almost completely resolve this problem. Unfortunately,
such donors are still associated with substantially inferior outcome
(5, 12, 13).
Basically, the results we have obtained underline the feasibil-
ity of including HLA-C as a primary matching criterion in donor
selection for a European-Caucasian population today and, at the
same time, justify and stimulate the further growth of all donor
registries.
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Furthermore, we were able to quantify the impact of the res-
olution of HLA-C typing on the identification rate of matched
donors. Theoretically, in the context of matching for four other
loci including HLA-B, low resolution HLA-C already reflects most
of the additional polymorphism. As a consequence, it will remain
difficult to decide if HLA-C matching at low resolution is suffi-
cient or not. In practice, however, HLA-C typing should always
be performed upfront for donors at the highest affordable res-
olution to expedite the search process and to avoid unnecessary
HLA-C mismatching (17). With regard to the permissible HLA-
C mismatch HLA-C*03:03 vs. 03:04 discussed in (35), a variant
of the calculations reported here shows that in more than half of
the cases where a low resolution HLA-C mismatch can be avoided
but a high-resolution HLA-C mismatch must be accepted, this
mismatch can be chosen to be HLA-C*03:03 vs. 03:04.
It is quite likely that these simulations based on a Ger-
man population, with little recent admixture, will basically hold
true for many similar populations of European-Caucasian back-
ground. However, it would be extremely interesting how these
HLA-C-related observations translate into fundamentally differ-
ent racial/ethnical groups, like those studied in (36). Unfortu-
nately, similar investigations at the global level are still hampered
by the lack of accessible multi-locus high-resolution HLA data for
most populations as well as their corresponding donor availability
rates. So a more realistic modeling of global donor procurement
rates remains a challenge for the future.
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